April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
1 citations
,
May 2019 in “Cytotherapy” The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
61 citations
,
April 2014 in “Radiation Research” RTA 408 cream protects mice from radiation skin damage.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
Isotretinoin effectively improved severe pityriasis rubra pilaris with complications.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
1 citations
,
November 2024 in “EMBO Reports” Deleting Gpr54 speeds up hair growth and regeneration.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy”
May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
May 2024 in “Reactions weekly”
Proretinal nanoparticles are a safe and effective way to deliver retinal to the skin.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
January 2024 in “Circulation” Certain genetic mutations can lower bad cholesterol and reduce heart disease risk, leading to effective cholesterol-lowering drugs.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
1 citations
,
December 2025 in “Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)” Spanlastics effectively deliver Rizatriptan Benzoate with high efficiency and controlled release.
10 citations
,
August 2020 in “Acta histochemica” All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.